羟考酮对腹腔镜下胆囊切除术术后胃肠功能影响

注册号:

Registration number:

ChiCTR2500109828 

最近更新日期:

Date of Last Refreshed on:

2025-09-25 15:12:40 

注册时间:

Date of Registration:

2025-09-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

羟考酮对腹腔镜下胆囊切除术术后胃肠功能影响

Public title:

The influence of oxycodone on gastrointestinal function after laparoscopic cholecystectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

羟考酮对腹腔镜下胆囊切除术术后胃肠功能影响

Scientific title:

The influence of oxycodone on gastrointestinal function after laparoscopic cholecystectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

魏宏 

研究负责人:

魏宏 

Applicant:

Wei Hong 

Study leader:

Wei Hong 

申请注册联系人电话:

Applicant telephone:

+86 759 2655 3111

研究负责人电话:

Study leader's
telephone:

+86 759 2655 3111

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

Weihong269@163.com

研究负责人电子邮件:

Study leader's E-mail:

weihong269@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

深圳市南山区桃园路89号

研究负责人通讯地址:

深圳市南山区桃园路89号

Applicant address:

No.89, Taoyuan Road, Nanshan District, Shenzhen, Guangdong

Study leader's address:

No.89, Taoyuan Road, Nanshan District, Shenzhen, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳市南山区人民医院

Applicant's institution:

Shenzhen Nanshan District People's Hospital

研究负责人所在单位:

深圳市南山区人民医院

Affiliation of the Leader:

Shenzhen Nanshan People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科研伦审[ky-2025-0819001]号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

华中科技大学协和深圳医院科研伦理委员会

Name of the ethic committee:

Ethic Committee of Huazhong University of Science and Technology Union Shenzhen Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-08-19 00:00:00

伦理委员会联系人:

黄晓佳

Contact Name of the ethic committee:

Huang XiaoJia

伦理委员会联系地址:

深圳市南山区桃园路89号

Contact Address of the ethic committee:

No.89, Taoyuan Road, Nanshan District, Shenzhen, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 755 26664650

伦理委员会联系人邮箱:

Contact email of the ethic committee:

silvia1026@126.com

研究实施负责(组长)单位:

深圳市南山区人民医院

Primary sponsor:

Shenzhen Nanshan People's Hospital

研究实施负责(组长)单位地址:

深圳市南山区桃园路89号

Primary sponsor's address:

No.89, Taoyuan Road, Nanshan District, Shenzhen, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市南山区人民医院

具体地址:

深圳市南山区桃园路89号

Institution
hospital:

Shenzhen Nanshan People's Hospital

Address:

No.89, Taoyuan Road, Nanshan District, Shenzhen, Guangdong

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-raised

研究疾病:

阿片类药物导致的胃肠功能障碍  

Target disease:

Opioid-induced gastrointestinal dysfunction

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察羟考酮用于腹腔镜下胆囊切除术麻醉诱导时对患者胃肠功能恢复的影响,包括胃排空时间、首次排气时间、首次排便时间等指标,以明确羟考酮在该手术中应用的安全性和有效性,为优化麻醉诱导方案及促进术后胃肠功能恢复提供参考。  

Objectives of Study:

Observe the impact of oxycodone on the recovery of patients' gastrointestinal function during anesthesia induction for laparoscopic cholecystectomy, including indicators such as gastric emptying time, first flatus time, and first defecation time, so as to clarify the safety and effectiveness of oxycodone in this surgery. This study aims to provide a reference for optimizing anesthesia induction protocols and promoting postoperative gastrointestinal function recovery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.术前存在胃肠功能障碍病史,如肠梗阻、炎症性肠病等。
2.合并严重的心、肺、肝、肾功能障碍;
3.有阿片类药物过敏史或滥用史。

Exclusion criteria:

1. History of gastrointestinal dysfunction before surgery, such as intestinal obstruction, inflammatory bowel disease, etc. 2. Complicated with severe heart, lung, liver and kidney dysfunction; 3. History of opioid allergy or abuse.

研究实施时间:

Study execute time:

From 2025-09-15 00:00:00 To 2026-09-15 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-09-28 00:00:00 To 2026-09-15 00:00:00

干预措施:

Interventions:

组别:

B组(舒芬太尼组)

样本量:

34

Group:

Group B (Sufentanil Group)

Sample size:

干预措施:

麻醉诱导给予舒芬太尼

干预措施代码:

Intervention:

Sufentanil is administered for anesthesia induction.

Intervention code:

组别:

A组(羟考酮组)

样本量:

34

Group:

Group A (Oxycodone Group)

Sample size:

干预措施:

术前给予羟考酮用于麻醉诱导

干预措施代码:

Intervention:

Oxycodone is administered preoperatively for anesthesia induction.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

深圳市南山区人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shenzhen Nanshan People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

胃排空速度

指标类型:

主要指标

Outcome:

Gastric emptying rate

Type:

Primary indicator

测量时间点:

术后、术后10min、术后20min、术后30min

测量方法:

术后在复苏室予患者行胃排空实验min、并用超声测量患者术后、术后10min、术后20min、术后30min胃窦面积来判断患者胃排空速度。

Measure time point of outcome:

Postoperatively, 10 minutes postoperatively, 20 minutes postoperatively, 30 minutes postoperatively

Measure method:

After surgery, patients underwent a gastric emptying test in the recovery room, and ultrasound was used to measure the antral area postoperatively, 10 minutes postoperatively, 20 minutes postoperatively, and 30 minutes postoperatively to determine the patients' gastric emptying rate.

指标中文名:

术后首次排气时间

指标类型:

次要指标

Outcome:

First exhaust time after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

首次排便时间

指标类型:

次要指标

Outcome:

First defecation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后首次下床活动时间

指标类型:

次要指标

Outcome:

First time of getting out of bed activity after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃肠功能障碍评分

指标类型:

次要指标

Outcome:

Gastrointestinal dysfunction score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究员用计算机生成的随机数字表,将患者随机分为两组

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients were randomly divided into two groups using a random number table generated by researchers with a computer.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

患者、研究观察者及数据收集者均对分组情况保持双盲

Blinding:

Patients, study observers, and data collectors all maintained double-blind grouping.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例收集表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-09-25 15:12:23